August 21, 2025 - Altanine, Inc., a pharmaceutical company advancing proprietary drug delivery technologies across high-growth therapeutic areas, today announced the appointment of Pedro Gutiérrez-Castrellón, MD, MSc, DSc, MBA, to its Scientific Advisory Board (SAB).
Dr. Gutiérrez-Castrellón brings more than 25 years of translational health research experience, having led over 70 randomized clinical trials across maternal, pediatric, and adult populations. He currently serves as CEO of Elemental Translational Research SAPI de C.V. and Chief Medical Officer at U.S.-based Cellarion LLC. His expertise will support Altanine’s efforts to validate its drug delivery technologies in clinical settings and prepare for future development pathways.
“I look forward to contributing to Altanine’s work in drug delivery,” said Dr. Gutiérrez-Castrellón. “The company’s focus on improving patient experience and outcomes is aligned with my own commitment to advancing clinical research.”
Altanine’s SAB is now comprised of Richard Evan Greenberg, MD, FACS; Jason Mellad, PhD; John Macor, PhD; Richard Pratley, MD; Franklin D. Pratt, MD, MPHTM, FACEP; and Dr. Gutiérrez-Castrellón. Together, they provide diverse perspectives across medicine, research, and product development that will guide Altanine in its mission to advance innovative drug delivery technologies that improve patient comfort and outcomes while positioning the company to address growing therapeutic markets.
“Pedro’s clinical research experience adds valuable insight to our advisory board,” said George Hornig, Chairman of the Board of Altanine. “His contributions will help strengthen our approach as we continue developing next-generation drug delivery solutions.”
“Having an advisor with Pedro’s background in clinical trial management will be very helpful as we advance our programs,” said Charles J. Andres, Ph.D., J.D., Chief Executive Officer of Altanine. “His perspective will support our efforts to bring meaningful innovations to patients and the healthcare community.”
With the addition of Dr. Gutiérrez-Castrellón, Altanine’s SAB is well-positioned to help guide the company’s clinical programs, accelerate development of its drug delivery pipeline, and lay the foundation for future innovations in patient-centered therapeutics.
Altanine is a pharmaceutical company with a platform of proprietary drug delivery technologies for widely prescribed drugs which improve bioavailability, reduce side effects and enhance patient comfort and convenience. Altanine’s strategic focus targets large and expanding treatment markets including diabetes, weight control, sexual wellness and neurocare. With its proprietary enteric coatings and delivery systems, Altanine positions itself as a leader in next generation drug delivery innovations.
For the latest updates on Altanine’s clinical progress and pipeline, visit: www.altanine.com
